Mounjaro Weight Loss by Week: Full Timeline

Introduction

Mounjaro® is tirzepatide approved for type 2 diabetes, dosed once weekly. The same molecule is sold as Zepbound® for weight management. The clinical results overlap closely. The SURPASS-2 trial (Frias et al. 2021 NEJM) and SURMOUNT-1 (Jastreboff et al. 2022 NEJM) give the week-by-week curves.

SURMOUNT-1 produced a mean 20.9% body weight loss at 72 weeks on tirzepatide 15 mg. That’s the strongest result from any GLP-1 trial published to date. SURPASS-2 (diabetes population, lower doses) produced 12.4% loss at 40 weeks.

Real-world patients on Mounjaro for weight loss usually track close to the SURMOUNT-1 curve when dosing matches the trial. This article walks through what to expect from week 1 through week 72 on standard tirzepatide titration.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What’s the Standard Mounjaro Dose Ramp?

The label titration starts at 2.5 mg weekly for 4 weeks, then 5 mg for 4 weeks, then increases by 2.5 mg every 4 weeks as tolerated. Available doses are 2.5, 5, 7.5, 10, 12.5, and 15 mg.

Quick Answer: SURMOUNT-1 (Jastreboff et al. 2022 NEJM): mean 20.9% loss at 72 weeks on 15 mg

The 2.5 mg starting dose is a tolerance dose. It’s not generally enough for full appetite suppression but it lets the body adjust to the molecule. Most patients have mild GI side effects (nausea, fullness, constipation) that resolve within a week or two.

Maintenance doses are 5, 10, or 15 mg. The trial outcomes scale with dose: 15 mg produced 20.9% loss in SURMOUNT-1, 10 mg produced 19.5%, and 5 mg produced 15%. Higher dose, better results, but also more side effects for many patients.

Some patients reach 15 mg quickly. Others get stuck at 7.5 or 10 mg because of GI tolerance. Either pattern can still produce good results.

Weeks 1-4: What Happens on 2.5 Mg?

Mean weight loss in SURMOUNT-1 by week 4 was about 2-3% of starting body weight. For a 240 lb starting weight, that’s 5-7 lb.

The 2.5 mg dose produces meaningful appetite suppression for many patients even though it’s the starting dose. Tirzepatide’s dual GIP/GLP-1 mechanism appears to activate appetite circuits at a lower threshold than pure GLP-1 drugs.

Most patients notice reduced food cravings and earlier fullness within the first 7-10 days. The clearest behavioral marker is portion size dropping without conscious effort.

Side effects are typically mild at 2.5 mg. The biggest issue is constipation, which affects a meaningful share of patients and is worth addressing early with hydration and fiber.

Weeks 5-12: Moving up the Dose Ladder

By week 12, SURMOUNT-1 patients on the 15 mg arm averaged about 8% body weight loss. Patients still in titration had reached 7.5 mg or 10 mg by this point.

For a 240 lb starting weight, week 12 lands around 220 lb (20 lb down). For a 200 lb starting weight, week 12 lands around 184 lb (16 lb down).

This is the dose ramp period where many patients first notice substantial appetite changes. The 5 mg and 7.5 mg doses produce stronger satiety than 2.5 mg, and the calorie deficit becomes more obvious.

GI side effects often flare with each dose increase, then settle within 7-10 days. Patients who can’t tolerate a dose increase typically pause at the prior dose for an extra 4 weeks rather than reverse.

Weeks 13-24: Hitting Maintenance Dose

Most patients reach their target maintenance dose between weeks 16-24 depending on tolerability. By week 24, SURMOUNT-1 mean cumulative loss on the 15 mg arm was around 14%.

Once on full dose, weight loss rate is at its highest. The combination of strong appetite suppression and a still-large residual deficit produces 1-3 lb per week of loss for most patients.

Body composition starts shifting visibly. Clothes fit differently. Tape measurements at waist and hips usually drop faster than scale weight implies because body fat is mobilizing.

This is the window where most patients see the most dramatic visible change. Energy levels often improve as body weight drops and metabolic markers normalize.

Weeks 24-40: The Peak Loss Zone

Between weeks 24 and 40, SURMOUNT-1 patients on 15 mg moved from about 14% to about 18% cumulative loss. That’s the steepest part of the curve.

This is where the body composition work matters most. Adding resistance training 2-3x per week during this window preserves lean mass and supports metabolic rate. The drug does the appetite work but it doesn’t build or hold muscle on its own.

Adequate protein intake (1.2-1.6 g/kg body weight) compounds the resistance training effect. Most patients fall short on protein without tracking.

Side effects typically stabilize by month 5-6. Most patients tolerate 15 mg without ongoing GI issues by this point, though occasional flares with new foods are normal.

Weeks 40-52: Into the Slow Zone

By week 52, SURMOUNT-1 cumulative loss was approaching 19%. The slope from week 40 to week 52 is less steep than weeks 24 to 40.

Metabolic adaptation, hunger adaptation, and a smaller residual deficit all contribute to the slowdown. This is normal and expected. It’s not a treatment failure.

For patients who are at goal by this point, the question becomes maintenance. For patients who still have weight to lose, the next 20 weeks are where the trial curve produces another 2-3 percentage points.

Real-world patients sometimes plateau here. Tracking food carefully for 4-6 weeks usually surfaces calorie creep. Many “plateaus” resolve with tighter tracking alone.

Key Takeaway: 36.2% of SURMOUNT-1 patients hit 25%+ loss at 72 weeks on 15 mg

Weeks 52-72: The SURMOUNT-1 Endpoint

SURMOUNT-1 ran 72 weeks and reported 20.9% mean cumulative loss at endpoint on 15 mg. The curve was still trending down at study close, suggesting more loss was available with continued treatment.

Top responders in SURMOUNT-1 hit 30%+ body weight loss by week 72. About 16% of patients on 15 mg crossed that threshold. The top quartile averaged above 28%.

Past 72 weeks, the limited extension data suggests another 2-3 percentage points of loss is possible in months 18-24 for adherent patients on high dose. Beyond that the curve flattens.

If you’ve hit goal weight by week 72, you’re on the maintenance question. If you still have more to lose, options include continuing at full dose, adding resistance training and protein, or recalibrating food intake.

What Does Mounjaro vs Zepbound Mean for the Timeline?

Same molecule (tirzepatide), same dosing, same expected curve. The labels differ: Mounjaro for type 2 diabetes, Zepbound for chronic weight management. Insurance coverage differs too.

Patients without diabetes typically need Zepbound (or compounded tirzepatide) for the weight loss indication. Patients with type 2 diabetes can get Mounjaro covered for the diabetes indication, with weight loss as a secondary benefit.

The molecule is identical so the week-by-week curve is identical at matched dose. SURMOUNT-1 was the Zepbound trial and SURPASS was the Mounjaro trial program, but the underlying pharmacology is the same.

Compounded tirzepatide from a licensed pharmacy uses the same active ingredient at matched dose. TrimRx offers compounded tirzepatide as part of a personalized treatment plan.

What If Your Timeline Is Slower Than SURMOUNT-1?

Real-world patients commonly run 3-5 percentage points below the trial mean at any given week. The reasons are titration pauses, missed doses, supply gaps, and weaker lifestyle adherence.

If you’re at 5% loss by week 24 instead of 14%, you’re below average but still progressing. If you’re at 1% by week 24 on a stable dose, you’re a likely partial responder.

Early response is the best predictor. If you’ve lost 5%+ by week 12, the probability of being in the upper half at week 72 is high. If you’ve lost less than 2% by week 12, talk to your clinician.

How Does Mounjaro Stack up Against Semaglutide Week-by-week?

SURMOUNT-5 (Aronne et al. 2025 NEJM) ran the head-to-head: tirzepatide 20.2% vs semaglutide 13.7% at 72 weeks. The tirzepatide curve was below (better than) the semaglutide curve at every measured timepoint.

The gap shows up early. By week 12, tirzepatide patients were typically 1-2 percentage points ahead. The gap widened through week 36 and held through week 72.

For patients prioritizing maximum weight loss, tirzepatide has the stronger evidence. For patients prioritizing CV outcomes data, semaglutide currently has more (SELECT trial). Most clinicians choose tirzepatide for weight-loss-primary indications and semaglutide for cardiovascular-primary indications.

Bottom line: SURMOUNT-5 (Aronne et al. 2025 NEJM): tirzepatide 20.2% vs semaglutide 13.7% at 72 weeks

FAQ

How Much Weight Will I Lose in the First Month on Mounjaro?

SURMOUNT-1 patients averaged 2-3% loss by week 4 on 2.5 mg. For a 240 lb start, that’s 5-7 lb. Individual range is wide. Some lose 10+ lb in month 1, others lose 2-3 lb.

What’s the Average Mounjaro Weight Loss at 6 Months?

Around 14% on the 15 mg arm based on SURMOUNT-1, with most patients having titrated up by then. Lower doses produce proportionally less: about 10% on 5 mg, 12% on 10 mg.

How Much Weight Loss Should I Expect at 1 Year on Mounjaro?

The 52-week SURMOUNT-1 number on 15 mg was approximately 18-19% mean cumulative loss. Top responders hit 25%+. Partial responders at the same dose hit 8-10%.

Why Does Mounjaro Produce More Weight Loss Than Semaglutide?

The dual GIP/GLP-1 mechanism activates more appetite-suppressing and metabolic pathways than pure GLP-1 alone. SURMOUNT-5 showed a 6.5 percentage point advantage for tirzepatide head-to-head.

Can I Stay on 5 Mg If 10 or 15 Mg Is Too Rough?

Yes. SURMOUNT-1 reported 15% mean loss on the 5 mg arm at 72 weeks, which is still substantial. Lower doses are reasonable maintenance options if higher doses produce intolerable side effects.

How Long Should I Stay on Mounjaro After Hitting My Goal?

Most patients stay on a maintenance dose long-term. Stopping typically produces gradual regain over 12-18 months, mirroring what STEP 4 showed for semaglutide. There’s no clean published exit protocol.

Is Compounded Tirzepatide the Same as Mounjaro Week-by-week?

The molecule is identical. When dosing matches and the pharmacy is licensed, the expected weekly curve should match. Real-world adherence and supply consistency are the main practical differences.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.